DexCom Inc
DXCM
Company Profile
Business description
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
Contact
6340 Sequence Drive
San DiegoCA92121
USAT: +1 858 200-0200
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
11,100
Stocks News & Analysis
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
We’ve raised our fair value estimate of Lilly stock.
stocks
OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year
Plus, whichever AI company IPOs first defines what “good” looks like.
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,970.00 | 5.90 | -0.07% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,652.14 | 790.33 | 1.62% |
| FTSE 100 | 10,378.82 | 165.71 | 1.62% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 24,892.31 | 219.07 | 0.89% |
| Nikkei 225 | 59,653.62 | 368.70 | 0.62% |
| NZX 50 Index | 12,961.65 | 58.34 | 0.45% |
| S&P 500 | 7,209.01 | 73.06 | 1.02% |
| S&P/ASX 200 | 8,749.90 | 1.10 | -0.01% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |